UBS Group’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

UBS Group’s Portfolio PAND Stock Details PAND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,068	Closed	-$124K	–	10399
2021 Q1	$124K	Buy	+2,068	New	+$74.9K	﹤0.01%	5799
2020 Q4	–	Sell	-5	Closed	–	–	9040
2020 Q3	$0	Buy	+5	New	+$85	﹤0.01%	8687

UBS Group's PAND Position: Q2 2021 in Review

UBS Group sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 2,068 shares — an estimated $124K sold.

UBS Group first reported a position in PAND in Q3 2020 and held it in 2 quarters. The position peaked at $124K in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

UBS Group reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
UBS Group sold 2,068 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $124K.
UBS Group first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 2 quarters.
UBS Group's Pandion Therapeutics Inc. Common Stock position peaked at $124K in Q1 2021.
0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on UBS Group's 13F filing for Q2 2021, filed 13 Aug 2021.